Venetoclax With Hypomethylating Agents in Newly Diagnosed AML Unfit for Intensive Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Azacitidine
Related studies linked through entity extraction aliases.
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
A Randomized Phase II Selection Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative Neoplasms
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1
Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia
- Status
- RECRUITING
- Phase
- PHASE1
Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
- Status
- RECRUITING
- Phase
- PHASE2/PHASE3
Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation
- Status
- RECRUITING
- Phase
- PHASE1
Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML
- Status
- RECRUITING
- Phase
- NA
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI)
- Status
- RECRUITING
- Phase
- PHASE3
VAH vs VA in Newly Diagnosed Elderly AML
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3